Why the Fisher & Paykel Healthcare share price just hit a 52-week high

The Fisher & Paykel Healthcare share price has hit a 52-week high following regulatory clearance for Vitera and raised guidance for FY20.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price has hit a 52-week high of $17.71 in Tuesday trade. Investors have bid up the company's share price this week following the release of 2 bullish announcements yesterday.

The first announcement revealed that the company has received regulatory clearance in the United States (US) to sell its new full-face mask. The second announcement was an upgrade to earnings guidance for FY20. 

Vitera regulatory clearance

Fisher & Paykel Healthcare has received regulatory clearance in the United States to sell its F&P 'Vitera' mask, which is used to treat obstructive sleep apnea. The new mask redefines mask performance via a combination of unique technologies that provide high levels of stability and durability. 

Vitera is already available for sale in Australia, Canada, New Zealand and Europe. The new mask is also expected to be available for sale in other markets once regulatory approval is received.

In the United States, the company received regulatory clearance to sell Vitera faster than the timeframe it had previously guided for. As a result, this has become a meaningful contributor to raised guidance for FY20. 

FY20 guidance lifted

For the financial year ending 31 March 2020, Fisher & Paykel Healthcare expects operating revenue to be around $1.19 billion and net profit after tax to fall in the range of $255 million to $265 million. The guidance assumes a NZD/USD exchange rate of around 63 cents for the remaining part of the financial year.  

The company had previously guided for FY20 operating revenue to be around $1.17 billion and net profit after tax to be between $245 million to $255 million. That guidance was based on an assumed NZD/USD exchange rate of 64 cents. 

Management also noted that there are no changes to revenue and earnings guidance for the first half of FY20. The full year guidance incorporates a further weakening of the NZ dollar and an adjustment to the projected research and development tax credit. 

Foolish takeaway

Fisher & Paykel Healthcare shares have now risen 42% in 2019. The company remains one of the best healthcare stocks on the Australian market alongside CSL Limited (ASX:CSL), Cochlear Limited (ASX: COH) and major competitor ResMed Inc. (ASX: RMD).

Tim Katavic owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »